Telogen effluvium is the medical term for a diffuse, temporary hair shedding event triggered by a physiological shock or change. The hair follicle operates on a cycle: anagen (active growth), catagen (transition), and telogen (resting and shedding). Under normal conditions, roughly 85–90% of follicles are in anagen at any given time, with the remaining 10–15% resting in telogen and preparing to shed.
When the body experiences a significant physiological stressor — rapid weight loss, major surgery, childbirth, severe illness, extreme caloric restriction, hormonal shift — it reads this as a survival signal. In response, a larger-than-normal proportion of follicles simultaneously exit the growth phase and enter telogen. Two to four months later, those follicles shed their hair at the same time. The shed appears sudden and alarming, but it actually began silently weeks before.
GLP-1 medications trigger this mechanism through a combination of factors: the rapid caloric deficit (even when medically managed), the speed of weight change, the hormonal and metabolic shifts that accompany significant weight loss, and in some cases the nutritional gaps that can develop when appetite suppression reduces overall food intake.
The critically important point: telogen effluvium is almost always temporary. The follicles that shifted to telogen are not damaged. They rest, shed, and — when the physiological trigger stabilizes — return to anagen. The hair regrows. The professional routine doesn't prevent this from happening, but it does three things: it reduces the rate of shed during the active phase, it protects the scalp environment so follicles can return to anagen efficiently, and it strengthens the new growth that comes in during recovery.